Oct 22 (Reuters) - Moderna (MRNA.O), opens new tab said on Wednesday it would stop developing its experimental vaccine to prevent cytomegalovirus, a virus that can cause birth defects, after it failed ...
Findings showed the study did not meet its primary endpoint of preventing CMV infection in seronegative participants. Topline results were announced from a phase 3 study evaluating Moderna’s ...
CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results